Study of SYS6026 injection for high-grade cervical lesions linked to HPV 16 or 18
Part of Cancer, Infections, Women’s health & pregnancy clinical trials.
This study tests an investigational injection called SYS6026 for people with high-grade cervical precancerous lesions (CIN 2 or 3) caused by HPV types 16 or 18. The goal is to see if the injection can help the body clear the HPV and reduce or eliminate the abnormal cells, possibly avoiding surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a cervical infection with HPV type 16 and/or 18, confirmed by a test.
- You must have a biopsy showing high-grade cervical lesions (CIN 2 or CIN 3) within the last 3 months.
- The doctor must be able to see the entire area where the cervix meets the cervical canal and the lesions must be large enough to be observed during the study.
- You must agree to have a biopsy before starting and a follow-up biopsy or surgery at 36 weeks after the first injection.
- You must be in generally good health, with normal blood counts, liver, kidney, and heart function, and no uncontrolled high blood pressure or fever.
- If you can become pregnant, you must use reliable birth control during the study and for at least one year after the last dose, and have a negative pregnancy test before starting.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental vaccine (RG002) for women with cervical pre-cancer caused by HPV types 16 or 18. The vaccine is designed to help the body fight the virus and potentially clear the pre-cancerous cells, possibly avoiding more invasive treatments.
This trial tests whether a vaccine against HPV can help prevent pre-cancerous lesions from coming back after you've had them. It's for people who have had high-grade pre-cancerous lesions but haven't yet been treated for them.
This trial tests an injection called BBM-C101 for women with high-grade cervical precancerous lesions linked to HPV types 16 or 18. The goal is to see if it can safely help the body clear these abnormal cells and prevent them from becoming cancer.
This trial tests a new vaccine (pBI-11) given with a device that uses mild electric pulses to help the vaccine enter cells. It is for people who have HPV16 or 18 but no high-grade cervical changes.
This study tests an investigational drug called NWRD09 in women with high-grade cervical lesions caused by HPV16. The goal is to see if it can help eliminate the abnormal cells and reduce the risk of cervical cancer.
This Phase 1 study tests FluBHPVE6E7, a new treatment designed to help the immune system respond to HPV16. It mainly checks safety and the best dose, and may help your body clear or control HPV over time.
Hear when a new High-grade Cervical Intraepithelial Lesions trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.